Magnesium bis(2-(dodecyloxy)ethyl sulfate) | 63596-52-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 英文名称: Magnesium bis(2-(dodecyloxy)ethyl sulfate)
• 英文别名: magnesium;2-dodecoxyethyl sulfate
• CAS: 63596-52-1
• 化学式: C28H58MgO10S2
• 分子量: 643.2
• InChiKey: NOQOJKIYCAQVMC-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  6.42
• 重原子数：
  41
• 可旋转键数：
  28
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  168
• 氢给体数：
  0
• 氢受体数：
  10

文献信息

• [EN] COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL INHIBITORS OF EGFR [ERBB1] AND HER-2 [ERBB2]<br/>[FR] POLYTHÉRAPIE POUR LE TRAITEMENT DE CANCER AU MOYEN D'INHIBITEURS DE LA COX-2 ET D'INHIBITEURS DOUBLES DE L'EGFR [ERBB1] ET DE L'HER-2 [ERBB2]
  申请人：TRAGARA PHARMACEUTICALS INC

  公开号：WO2009042613A1

  公开（公告）日：2009-04-02

  Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject.

  本文描述了一种用于治疗癌症、肿瘤和肿瘤相关疾病的组合物和使用这些组合物的方法。
• ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20200030270A1

  公开（公告）日：2020-01-30

  The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.

  本发明涉及口服可改性释放药物剂型，包括氯化钠(3S)-3-(4-氯-3-[(2S,3R)-2-(4-氯苯基)-4,4,4-三氟-3-甲基丁酰]氨基}苯基)-3-环丙基丙酸酯，并涉及制备药物剂型的过程以及它们用于治疗和/或预防疾病的用途，特别是用于治疗和/或预防心脏、肾脏和肺部疾病、中枢神经系统疾病、纤维化和炎症性疾病以及代谢性疾病。
• [EN] CONTINUOUS COMBINATION THERAPY WITH SELECTIVE PROSTAGLANDIN EP4, RECEPTOR AGONISTS AND AN ESTROGEN FOR THE TREATMENT OF CONDITIONS THAT PRESENT WITH LOW BONE MASS<br/>[FR] POLYTHERAPIE CONTINUE AVEC DES AGONISTES SELECTIFS DES RECEPTEURS EP4 DE LA PROSTAGLANDINE ET UN OESTROGENE POUR LE TRAITEMENT DE PATHOLOGIES SE MANIFESTANT PAR UNE FAIBLE MASSE OSSEUSE
  申请人：PFIZER PROD INC

  公开号：WO2005060946A1

  公开（公告）日：2005-07-07

  This invention is directed to methods for treating conditions which present with low bone mass in a patient in need thereof using continuous combination therapy with a synergistically effective combination of an EP4 receptor selective agonist or a pharmaceutically acceptable salt thereof, such as 5-(3-2S-[3R-hydroxy­4-(3-trifluoromethyl-phenyl)-butyl]-5-oxo-pyrrolid in-1-yl}-propyl)-thiophene-2­carboxylic acid or a pharmaceutically acceptable salt thereof; and an estrogen or a pharmaceutically effective salt thereof. The present methods are useful for treating conditions that present with low bone mass including osteoporosis, osteotomy, osteoporotic fracture, childhood idiopathic bone loss, periodontitis and low bone mass and for enhancing bone healing following facial reconstruction, maxillary reconstruction or mandibular reconstruction, inducing vertebral synostosis, enhancing long bone extension, enhancing the healing rate of a bone graft or a long bone fracture or enhancing prosthetic ingrowth in a patient in need thereof.

  本发明涉及使用具有协同作用的EP4受体选择性激动剂或其药学上可接受的盐（例如5-（3-2S-[3R-羟基-4-（3-三氟甲基苯基）-丁基]-5-氧代吡咯烷-1-基}-丙基）-噻吩-2-羧酸或其药学上可接受的盐）和雌激素或其药学上有效的盐的连续联合疗法，用于治疗患有低骨密度的患者的疾病。本方法适用于治疗低骨密度症状，包括骨质疏松症、骨切开术、骨质疏松性骨折、儿童特发性骨质流失、牙周炎和低骨质量，以及增强面部重建、上颌重建或下颌重建后的骨愈合，诱导椎体融合，增强长骨延长，增强骨移植或长骨骨折的愈合速度或增强患者的假体生长。
• Intermittent administration of a growth hormone secretagogue
  申请人：Pfizer Products Inc.

  公开号：EP1186293A2

  公开（公告）日：2002-03-13

  The present invention relates to the intermittent administration of a growth hormone secretagogue to a patient and to kits for use therein.

  本发明涉及对患者间歇性施用生长激素分泌物及其使用的试剂盒。
• Composition comprising ocaperidone
  申请人：NEURO3D

  公开号：EP1690540A1

  公开（公告）日：2006-08-16

  The present invention relates to a composition comprising ocaperidone as an active substance and an effective amount of water-soluble polymers to increase solubility of ocaperidone. The present invention further relates to a therapeutic system for ocaperidone with a compartment for the drug formulation comprising said composition, and to a process for the preparation thereof as well as to the therapeutic use of said composition as antipsychotic drug. The present invention also relates to the solubilisation of ocaperidone in an aqueous medium with the aid of water soluble swellable polymers.

  本发明涉及一种组合物，该组合物包含作为活性物质的奥卡哌酮和有效量的水溶性聚合物，以增加奥卡哌酮的溶解度。本发明还涉及一种奥卡哌啶酮治疗系统，其药物制剂的隔室包含所述组合物，本发明还涉及其制备工艺以及所述组合物作为抗精神病药物的治疗用途。本发明还涉及借助水溶性可溶胀聚合物在水介质中增溶奥卡哌酮。